Sebastian Meerwein

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

Mark C. Genovese, Roy Fleischmann, Bernard Combe et al. · The Lancet · 2018 · 443 citations

Medicine, Internal Medicine, Pharmacotherapy +11

Efficacy and Safety of ABT‐494, a Selective JAK‐1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Mark C. Genovese, Josef S Smolen, Michael E. Weinblatt et al. · Arthritis & Rheumatology · 2016 · 201 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study

Hideto Kameda, Tsutomu Takeuchi, Kunihiro Yamaoka et al. · Lara D. Veeken · 2020 · 65 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +16

Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs

Vibeke Strand, Michael Schiff, Namita Tundia et al. · Arthritis Research & Therapy · 2019 · 56 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)

Hideto Kameda, Tsutomu Takeuchi, Kunihiro Yamaoka et al. · Arthritis Research & Therapy · 2021 · 28 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +13